Statin Drugs Benefit Heart Disease Patients, but May Cause Eye Disorders in Some
11/24/08 Portland, Ore.
Statin medications are used to lower patients’ cholesterol levels, thus helping to prevent coronary heart disease, stroke and death
Statin use has grown rapidly since 1992, and seems likely to increase in light of the recent, widely-reported Jupiter Study on the drugs’ benefits in patients with low cholesterol but elevated C-reactive protein. Eye disorders related to statins are rare, occurring in about 0.1 percent of patients (0.5 to 2.5 percent when gemfibrozil, another type of cholesterol-lowering drug, is taken simultaneously) but had not been systematically reported prior tothe study led by F.W. Fraunfelder, MD, of the Casey Eye Institute at Oregon Health and Science University. The research appears in the December issue of Ophthamology, the journal of the American Academy of Ophthamology.
Fraunfelder’s group analyzed statin-associated reports of double vision (diplopia), drooping of the upper eyelid (ptosis), and loss of full range of motion of the eyes (ophthalmoplegia) in the databases of the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the Food and Drug Administration. Since statins were known to cause skeletal muscle disorders in some patients, a similar affect was plausible in the eye muscles. The average patient age was 64.5 years, and the case reports included 143 males, 91 females, and 22 persons with gender unspecified. The average statin dose of patients who exhibited one or more eye disorder was within ranges recommended by drug manufacturers, and the average time from beginning of therapy to developing an adverse drug reaction (ADR) was 8.3 months. There were 23 cases of loss of eye range of motion; 8 cases of ptosis, and 18 cases of ptosis in conjunction with double vision; disorders in all patients apparently resolved completely when statins were discontinued. From the ADR reports, the researchers could not determine precisely which eye muscles were involved, or time needed to full recovery after statin discontinuation, for individual cases.
“We advise physicians prescribing statins to be aware that these eye disorders may result, and that medications should be discontinued if so. When a patient presents with one of these eye disorders, he should be rigorously evaluated to determine the cause and statin use should be taken into account,” Fraunfelder concludes.